BRIEF published on 09/16/2026 at 07:35, 9 days 19 hours ago Nicox: NCX 470 data presentation at the 2026 AAOpt Congress Phase 3 Ophthalmology Nicox NCX 470 AAOpt Congress
PRESS RELEASE published on 09/16/2026 at 07:30, 9 days 19 hours ago Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026 Nicox presents key data on NCX 470 at AAOpt Annual Meeting 2026, focusing on glaucoma management. Details on clinical trials and future conference participation Clinical Trials Ophthalmology Nicox NCX 470 AAOpt
BRIEF published on 09/11/2026 at 07:35, 14 days 19 hours ago Nicox's NCX 470 NDA Accepted for Review in China Ophthalmology NCX 470 Ocumension Therapeutics China Market NDA Review
PRESS RELEASE published on 09/11/2026 at 07:30, 14 days 19 hours ago Nicox Announces NCX 470 NDA in China Accepted for Review Nicox announces acceptance of NCX 470 NDA in China by NMPA for review. Regulatory decision expected 12-18 months post-submission. Details on Ocumension and NCX 470 milestones China Nicox NCX 470 Regulatory Decision NMPA
BRIEF published on 09/02/2026 at 07:35, 23 days 19 hours ago Nicox Extends Its Cash Flow Horizon Thanks to NCX 470 Ophthalmology NDA Nicox NCX 470 Cash Flow Horizon
BRIEF published on 09/02/2026 at 07:35, 23 days 19 hours ago Nicox Announces Financial Stability Extension Financial Update Ophthalmology Nicox NCX 470 Cash Runway
PRESS RELEASE published on 09/02/2026 at 07:30, 23 days 19 hours ago Nicox Announces Extension of Cash Runway Nicox extends cash runway with estimated €8.4 million as of 31 August 2026, supporting operations beyond Q1 2028. NCX 470 U.S. NDA approval milestone could fund operations into 2029 Financial Update Ophthalmology Nicox NCX 470 Cash Runway
BRIEF published on 08/27/2026 at 07:35, 29 days 19 hours ago Nicox: PDUFA date set for the NCX 470 in April 2027 FDA Glaucoma Nicox NCX 470 PDUFA
PRESS RELEASE published on 08/27/2026 at 07:30, 29 days 19 hours ago Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma Nicox announces April 2027 PDUFA date for NCX 470 in Glaucoma. Positive results from Phase 3 trials pave the way for potential FDA approval and commercial launch in H2 2027 FDA Approval Glaucoma Nicox NCX 470 PDUFA Date
BRIEF published on 08/10/2026 at 07:35, 1 month 15 days ago Nicox's NCX 470 NDA Submitted in China Nicox Glaucoma Treatment NCX 470 Ocumension China NDA
Published on 09/26/2026 at 01:00, 2 hours 3 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 2 hours 3 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 4 hours 48 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 9 hours 33 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 12 hours 3 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 00:01, 3 hours 1 minute ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 8 hours 33 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 17:30, 9 hours 33 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 09/25/2026 (French only)
Published on 09/25/2026 at 17:17, 9 hours 45 minutes ago Amendments to the Bond Terms and Conditions Have Been Implemented
Published on 09/25/2026 at 17:40, 9 hours 23 minutes ago Availability of the 2026 half-year financial report
Published on 09/24/2026 at 18:00, 1 day 9 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 1 day 9 hours ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 1 day 9 hours ago Cegedim first-half 2026 results: profitability continues to improve
